The disease severity and socio-economic impact of COPD is determined by acute exacerbations. More than 70% of COPD patients with acute exacerbations in primary care are treated with antibiotics, although the causal role of bacteria is often uncertain and evidence for use limited. Through population research, we want to optimize and personalize the risk-benefit ratio of antibiotic treatment in COPD.